As It Waits to Start HBV Trial, Arrowhead Plans Additional Drug Candidates | GenomeWeb

As it waits on regulators for clearance to begin a phase IIa trial of its flagship hepatitis B treatment ARC-520, Arrowhead Research is preparing to name two additional clinical candidates, with one unveiled around the end of the second quarter, companies officials said this week.

Also this week, Arrowhead filed a shelf registration to sell as much as $200 million in common stock, preferred stock, and/or warrants, which President and CEO Christopher Anzalone said would give the company the ability to fully develop ARC-520 with or without a partner.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.